EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR) announced today the initiation of a Phase 2 study of ADL5859, a novel delta opioid agonist in development for the treatment of pain. Study 33CL230 targets dental pain and is the first of several planned proof of concept studies designed to explore the analgesic efficacy of ADL5859 across a range of acute, inflammatory and neuropathic pain indications. Completion of Study 33CL230 is targeted for early 2008.
